Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Off-label Avastin in AMD: the European Commission gets involved

This article was originally published in SRA

Executive Summary

The controversy over the off-label use of Roche's Avastin (bevacizumab) in wet AMD has spread beyond national borders and is now on the EU agenda, after the European Commission said it was planning to launch a study of off-label prescribing to better understand the various aspects of off-label prescribing, which is not currently regulated at EU level.

Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS117759

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel